New knee osteoarthritis treatment shows promise in early human test

NCT ID NCT06539429

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing a new biological treatment called ANT-301 in 6 people with severe knee osteoarthritis. The main goal is to check safety, but researchers will also measure pain and knee function. If safe, larger studies could follow to see if it truly helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ANT-301 (a biological product made from cells)
What this could lead to
If it works, this could point toward a new treatment to control knee osteoarthritis pain and improve function.
What could go wrong
This is a very early, tiny trial with only 6 people. It mainly checks safety, not effectiveness. The treatment may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS, KNEE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Seoul National University

    Seoul, Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.